You are here

Investor Relations

Home

Jeffrey Leiden, Chairman, President and CEO

Date	Title and Summary
Toggle SummaryJul 8, 2004	48-Week Efficacy Comparison of Lexiva/Ritonavir QD vs. Nelfinavir BID in Therapy-Naive HIV+ Patients: Results Published in AIDS 48-Week Efficacy Comparison of Lexiva/Ritonavir QD vs. Nelfinavir BID in Therapy-Naive HIV+ Patients: Results Published in AIDS Research Triangle Park, NC, July 8, 2004 -- The protease inhibitor (PI) LEXIVA(R) (fosamprenavir calcium) dosed with ritonavir (LEXIVA/r) once-daily (QD) as part of a General Business
Toggle SummaryApr 15, 2010	59 Percent of Patients Overall Achieved SVR with Telaprevir-Based Regimens in Study 107 After Not Achieving SVR with at Least One Prior Course of Treatment for Hepatitis C Virus Infection <i>-56% of prior treatment null responder patients achieved SVR with a 48-week telaprevir-based regimen-</i> <br /> <i>-97% of prior treatment relapsers and 55% of prior treatment partial responders achieved SVR with 24-week or 48-week telaprevir-based regimens-</i> <br /> HCV
Toggle SummarySep 7, 2010	65% of People Whose Prior Treatment for Hepatitis C Was Unsuccessful Achieved SVR (Viral Cure) with Telaprevir-Based Therapy in Phase 3 REALIZE Study <i>-17% of people achieved SVR with pegylated-interferon and ribavirin alone in the control arm-</i> <br /> <i>-Safety and tolerability results were consistent with prior Phase 3 studies-</i> <br /> <i>-Completion of rolling New Drug Application submission on track for the fourth quarter 2010-</i> <br /> HCV